Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Myeloid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Breast Neoplasms 19Lung Neoplasms 11Stomach Neoplasms 9Colorectal Neoplasms 9Pancreatic Neoplasms 8Endometrial Neoplasms 8Ovarian Neoplasms 7Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms, Male 4Thyroid Neoplasms 3Sarcoma 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Melanoma 3Gallbladder Neoplasms 3Colonic Neoplasms 3Carcinoma, Ovarian Epithelial 3Vulvar Neoplasms 2Vipoma 2Vaginal Neoplasms 2Uterine Neoplasms 2

Interventions

Gemcitabine 2ruxolitinib 1rucaparib 1pemigatinib 1pembrolizumab 1motexafin gadolinium 1abiraterone 1Watchful Waiting 1Vorinostat 1Trastuzumab 1Tinzaparin 1TTI-621 1Rituximab 1Paclitaxel 1Nivolumab 1Ipilimumab 1In Situ Hybridization, Fluorescence 1INCB057643 1Fentanyl 1Epoetin Alfa 1Doxorubicin 1Docetaxel 1Cisplatin 1CTLA-4 Antigen 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Trastuzumab × Thoracic × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡